Analysts Set Schrodinger, Inc. (NASDAQ:SDGR) Price Target at $20.50

Shares of Schrodinger, Inc. (NASDAQ:SDGR) have earned an average rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $20.50.

SDGR has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Schrodinger from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group started coverage on shares of Schrodinger in a research note on Friday, August 14th. They issued a “neutral” rating and a $19.00 price objective for the company. Finally, Weiss Ratings raised Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th.

Insider Transactions at Schrodinger

In other Schrodinger news, insider Karen Akinsanya sold 31,599 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $29.37, for a total value of $928,062.63. Following the completion of the sale, the insider owned 69,956 shares in the company, valued at approximately $2,054,607.72. The trade was a 31.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Schrodinger

A number of institutional investors have recently modified their holdings of SDGR. Rubric Capital Management LP boosted its stake in Schrodinger by 43.8% during the 1st quarter. Rubric Capital Management LP now owns 6,000,000 shares of the company’s stock worth $68,160,000 after purchasing an additional 1,828,502 shares during the period. Quantinno Capital Management LP acquired a new position in Schrodinger in the first quarter valued at $1,978,000. Tejara Capital Ltd acquired a new position in Schrodinger in the second quarter valued at $4,553,000. BlackRock Inc. purchased a new stake in shares of Schrodinger in the second quarter valued at about $170,978,000. Finally, Ieq Capital LLC acquired a new stake in shares of Schrodinger during the second quarter worth about $1,160,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Schrodinger Stock Up 4.2%

Shares of SDGR opened at $30.24 on Friday. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -40.86 and a beta of 1.69. Schrodinger has a 52-week low of $10.94 and a 52-week high of $31.03. The stock has a 50 day moving average price of $18.79 and a 200 day moving average price of $15.33.

Schrodinger (NASDAQ:SDGR) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.49. The company had revenue of $58.89 million for the quarter, compared to analysts’ expectations of $47.19 million. Schrodinger had a negative net margin of 20.98% and a negative return on equity of 16.37%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.65) earnings per share. On average, equities analysts anticipate that Schrodinger will post -1.5 EPS for the current fiscal year.

About Schrodinger

Schrödinger, Inc develops computational software designed to accelerate drug discovery and materials science research. Its platform uses physics-based modeling, machine learning and related computational methods to help scientists analyze molecular structures, predict interactions and identify potential compounds for further development.

The company’s software products support a range of research activities, including molecular modeling, virtual screening, structure-based drug design, free-energy calculations and collaborative data management.